S&G Foundation Buys Shares of 435,749 Shattuck Labs, Inc. $STTK

S&G Foundation bought a new stake in shares of Shattuck Labs, Inc. (NASDAQ:STTK) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 435,749 shares of the company’s stock, valued at approximately $3,024,000. Shattuck Labs comprises about 0.1% of S&G Foundation’s holdings, making the stock its 15th biggest position.

A number of other institutional investors and hedge funds have also recently modified their holdings of STTK. Virtu Financial LLC purchased a new position in Shattuck Labs during the 3rd quarter valued at $38,000. AQR Capital Management LLC boosted its stake in shares of Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after purchasing an additional 31,355 shares during the period. Qube Research & Technologies Ltd bought a new position in shares of Shattuck Labs in the second quarter worth about $44,000. Squarepoint Ops LLC purchased a new position in Shattuck Labs in the 3rd quarter worth about $46,000. Finally, Bridgeway Capital Management LLC lifted its holdings in Shattuck Labs by 147.5% during the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock valued at $73,000 after buying an additional 55,000 shares in the last quarter. 58.74% of the stock is owned by institutional investors.

Insider Activity at Shattuck Labs

In other news, Director Clay B. Siegall purchased 62,500 shares of the business’s stock in a transaction on Tuesday, June 9th. The shares were acquired at an average cost of $4.00 per share, with a total value of $250,000.00. Following the completion of the acquisition, the director owned 318,608 shares of the company’s stock, valued at $1,274,432. This trade represents a 24.40% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Arundathy N. Pandite sold 30,000 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $7.01, for a total value of $210,300.00. Following the transaction, the insider directly owned 136,219 shares in the company, valued at approximately $954,895.19. The trade was a 18.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 53,875 shares of company stock valued at $379,305 over the last 90 days. Insiders own 8.79% of the company’s stock.

Shattuck Labs Stock Performance

STTK stock opened at $7.53 on Friday. The firm has a market cap of $755.71 million, a price-to-earnings ratio of -14.76 and a beta of 1.08. The firm has a 50-day simple moving average of $6.75 and a two-hundred day simple moving average of $6.07. Shattuck Labs, Inc. has a one year low of $0.90 and a one year high of $8.33.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). As a group, equities analysts predict that Shattuck Labs, Inc. will post -0.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on STTK. Wall Street Zen cut shares of Shattuck Labs from a “buy” rating to a “hold” rating in a research report on Saturday, August 15th. Wedbush lifted their price target on shares of Shattuck Labs from $8.00 to $11.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Weiss Ratings upgraded Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 16th. Leerink Partners started coverage on Shattuck Labs in a research note on Monday, July 20th. They issued an “outperform” rating and a $16.00 price objective on the stock. Finally, JPMorgan Chase & Co. assumed coverage on Shattuck Labs in a report on Friday, July 24th. They set an “overweight” rating and a $10.00 price objective on the stock. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Shattuck Labs has a consensus rating of “Moderate Buy” and a consensus target price of $12.12.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.